Japan· JP-2492423A2021
インスリンアスパルト（遺伝子組換え）［インスリンアスパルト後続１］
A medicinal product containing インスリンアスパルト（遺伝子組換え）［インスリンアスパルト後続１］, registered in Japan by サノフィ, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- インスリンアスパルト（遺伝子組換え）［インスリンアスパルト後続１］
- Manufacturer
- サノフィ
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
インスリンアスパルト（遺伝子組換え）［インスリンアスパルト後続１］ in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- United KingdomFiasp 100units/ml solution for injection 10ml vialsNovo Nordisk Ltd
- United States.Insulin Aspart Protamine and Insulin AspartA-S Medication Solutions
- BelgiumDazparda 100 U/mlGan & Lee Pharmaceuticals Europe
- FinlandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- SwedenDazparda 100 E/ml Injektionsvätska, lösning i förfylld injektionspennaGan & Lee Pharmaceuticals Europe GmbH
- IcelandFiaspNovo Nordisk A/S*
- PolandDazpardaGan & Lee Pharmaceuticals Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dazparda, Fiasp
- Liechtenstein · Dazparda, Insulin Aspart Sanofi
- Norway · Dazparda, Fiasp
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ad382679-114f-4d79-9929-604f68ebc1ca GET /v1/drugs/ad382679-114f-4d79-9929-604f68ebc1ca?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "３００単位１筒",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2492423A2021",
"category": "注射薬",
"price_yen": 674,
"generic_name": "インスリンアスパルト（遺伝子組換え）［インスリンアスパルト後続１］",
"product_name_jp": null,
"therapeutic_class": "2492",
"transitional_expiry": null
}See everything about インスリンアスパルト（遺伝子組換え）［インスリンアスパルト後続１］.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.